The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy

被引：0
|
作者：
Banerjee, S. N.
Thornhill, A.
Evans, D. B.
Littlewood-Evans, A. J.
Dowsett, M.
Martin, L-A
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Novartis Inst Biomed Res, Basel, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [11] PTK787/ZK 222584 (PTK/ZK), an oral tyrosine kinase inhibitor, has activity in patients with agnogenic myeloid metaplasia (AMM).
    Giles, Francis J.
    Carroll, Michael
    List, Alan
    Ferrajoli, Alessandra
    Thomas, Deborah
    Cortes, Jorge
    Feldman, Eric
    Roboz, Gail
    BLOOD, 2006, 108 (11) : 317B - 317B
  • [12] Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaplasia.
    Giles, FJ
    List, AF
    Roboz, GJ
    Tsimberidou, AM
    Laurent, D
    Reitsma, D
    Kowalski, MO
    Kantarjian, H
    Feldman, EJ
    BLOOD, 2003, 102 (11) : 922A - 923A
  • [13] Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK)
    Drevs, J
    Mross, K
    Reusch, P
    Peng, B
    Ball, H
    Henry, A
    Laurent, D
    Dugan, M
    Marme, D
    Unger, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S283 - S283
  • [14] A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma.
    Grimm, S. A.
    Chamberlain, M. C.
    Chandler, J.
    Muro, K.
    Rice, L.
    McCarthy, K.
    Rademaker, A.
    Helenowski, I. B.
    Johnston, S. K.
    Mrugala, M. M.
    Raizer, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [15] Biomarkers for the assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Comparison of preclinical data with results in phase I studies.
    Lee, L
    McSheehy, P
    Morgan, B
    Laird, G
    Allegrini, P
    Cozens, R
    Dugan, M
    Laurent, D
    Lebwohl, D
    Sharma, S
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6203S - 6203S
  • [16] A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas.
    George, D
    Jonasch, E
    Hart, L
    Lentz, J
    Parker, K
    Henry, A
    Pfister, C
    Dugan, M
    Laurent, D
    Clark, J
    Kaelin, WG
    Oh, W
    Kantoff, P
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3764S - 3764S
  • [17] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E. G.
    Younger, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B. P.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [18] A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors
    Sharma, Sunil
    Freeman, Burgess
    Turner, Jeanette
    Symanowski, James
    Manno, Phillip
    Berg, William
    Vogelzang, Nicholas
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 63 - 65
  • [19] A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis
    Malireddy, S. R.
    Chiorean, E.
    Foster, A.
    Jones, D.
    Waddell, M.
    Margol, M.
    Hall, S.
    Schneider, B.
    Sweeney, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [20] Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo
    Banerjee, Susana
    A'Hern, Roger
    Detre, Simone
    Littlewood-Evans, Amanda J.
    Evans, Dean B.
    Dowsett, Mitchell
    Martin, Lesley-Ann
    CLINICAL CANCER RESEARCH, 2010, 16 (16) : 4178 - 4187
12345